STUDY LED BY A*STAR'S GENOME INSTITUTE OF SINGAPORE FIND THE GENETIC CAUSES AS TO WHY CAUCASIANS ARE MORE LIKELY TO DEVELOP PSORIASIS THAN ETHNIC CHINESE

Findings open up possibilities for more targeted therapeutic cures for the disease

Singapore — A*STAR's Genome Institute of Singapore (GIS) led an international team of researchers from Singapore, China, USA and Europe to conduct the world's first large-scale, trans-ethnic, genome-wide analysis of DNA samples taken from Caucasian and Chinese populations for the study on the chronic skin disease, psoriasis[1]. Findings from the study were published in the scientific journal Nature Communications.

The researchers discovered four new genes that render people highly susceptible to psoriasis. By cross-referencing the sequence of 44 genes that influences psoriasis, which included the four recently discovered genes, between 8682 Caucasians and 5134 ethnic Chinese, the international team led by Prof Jianjun Liu, Deputy Director for Research Programmes and Senior Group Leader of Human Genetics found that 10 out of the 44 genes linked to psoriasis susceptibility were found only in Caucasians and not in ethnic Chinese. This finding helps to explain why psoriasis is ten times more prevalent in Caucasians than in ethnic Chinese populations.

The causes of psoriasis are not yet fully understood, but a number of risk factors are recognised as root causes, which include genetic and environmental factors, such as smoking, stress, obesity and alcohol consumption. The study takes some of the guesswork out of identifying the root cause responsible for the prevalence of psoriasis in Caucasian compared to ethnic Chinese populations.

"The discovery indicates that the ethnic difference of psoriasis prevalence is largely due to genetic causes," said Prof Liu. "With this knowledge, there is now a possibility to design therapeutic cures in an ethnic-specific fashion for psoriasis as there is currently no cure. The genetic differences in psoriasis susceptibility between ethnically varied populations call for more genetic studies within the Asian population."

"There are different types of treatments for psoriasis, with each addressing a different root cause of the disease. The only way for a patient to know which treatment best works for his or her condition is to try each over time – this will lead to added costs and time. The benefit of such genetic studies in psoriasis for example, allows the development of future genetic tests that will go a long way to help doctors take the guesswork out of figuring the root cause of disease and shortlist treatments that are known to be the most effective for that patient's condition," said Prof Huck-Hui Ng, Executive Director, GIS.


Notes to Editor:

The research findings described in the media release can be found in the scientific journal Nature Communications, under the title, "Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility" by Xianyong Yin1,2,3,4,28, Hui Qi Low5,28, Ling Wang5, Yonghong Li6, Eva Ellinghaus7, Jiali Han8,9,10, Xavier Estivill11, Liangdan Sun1,2,3,4, Xianbo Zuo1,2,3,4, Changbing Shen1,2,3,4, Caihong Zhu1,2,3,4, Anping Zhang1,2,3,4, Fabio Sanchez12, Leonid Padyukov13, Joseph J Catanese6, Gerald G Krueger14, Kristina Callis Duffin14, Sören Mucha7, Michael Weichenthal15, Stephan Weidinger15, Wolfgang Lieb16, Jia Nee Foo5, Yi Li5, Karseng Sim5, Herty Liany5, Ishak Irwan5, YikYing Teo17, Colin TS Theng18, Rashmi Gupta19, Anne Bowcock20, Philip L. De Jager21,22, Abrar A. Qureshi8,9,22, Paul I.W. de Bakker23,24, Mark Seielstad5,27,§, Wilson Liao19,§, Mona Ståhle12,§, Andre Franke7,§, Xuejun Zhang1,2,3,4,§ & Jianjun Liu2,3,4,5,25,26,§

1Institute of Dermatology and Department of Dermatology at No.1 Hospital, Anhui Medical University, Hefei, Anhui 230032, China.

2State Key Laboratory Incubation Base of Dermatology, Ministry of National Science and Technology, Anhui Medical University, Hefei, Anhui 230032, China.

3Key Lab of Dermatology (Anhui Medical University), Ministry of Education, Hefei, Anhui 230032, China.

4Collaborative Innovation Center for Complex and Severe Skin Diseases, Anhui Medical University, Hefei, Anhui 230032, China.

5Human Genetics, Genome Institute of Singapore, A*STAR, Singapore 138672, Singapore.

6Celera, Alameda, CA 94502, USA.
7Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Schittenhelm str. 12, 24105 Kiel, Germany.

8Clinical Research Program, Department of Dermatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

9Channing Laboratory, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

10Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.

11Genetic Causes of Disease Group, Centre for Genomic Regulation (CRG), Barcelona, E-08003, Spain.

12Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm17176, Sweden.

13Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm 17177, Sweden.

14Department of Dermatology, University of Utah, Salt Lake City, UT 84132, USA.

15Department of Dermatology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.

16Institute of Epidemiology and Biobank PopGen, Christian Albrechts University Kiel, Germany.

17Departments of Statistics & Applied Probability and Epidemiology & Public Health, National University of Singapore, Singapore 138672, Singapore.

18National Skin Centre, Singapore 308205, Singapore.
19Department of Dermatology, University of California San Francisco, San Francisco, CA 94115, USA.

20National Heart and Lung Institute, Imperial College, London, SW3 6LY, U.K.

21Program in Medical & Population Genetics, Broad Institute, Cambridge, MA 02138, USA.

22Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

23Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

24Department of Medical Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

25Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore.

26School of Life Sciences, Anhui Medical University, Hefei, Anhui 230032, China.

27Institute for Human Genetics, University of California San Francisco, San Francisco, CA 94143, USA.

28These authors contributed equally to this work.
§ These authors jointly supervised this work.



For media queries and clarifications, please contact:
Ms Winnie Lim
Head, Office of Corporate Communications
Genome Institute of Singapore, A*STAR
Tel:      +65 6808 8013
Email:[email protected]


About the A*STAR's Genome Institute of Singapore (GIS)

The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.

The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.

The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.

For more information about GIS, please visit: www.gis.a-star.edu.sg


About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that fosters world-class scientific research and talent to drive economic growth and transform Singapore into a vibrant knowledge-based and innovation driven economy.

In line with its mission-oriented mandate, A*STAR spearheads research and development in fields that are essential to growing Singapore's manufacturing sector and catalysing new growth industries. A*STAR supports these economic clusters by providing intellectual, human and industrial capital to its partners in industry.

A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities, located in Biopolis and Fusionopolis, as well as their vicinity. These two R&D hubs house a bustling and diverse community of local and international research scientists and engineers from A*STAR's research entities as well as a growing number of corporate laboratories.


For more information about A*STAR, please visit: www.a-star.edu.sg

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.